142 related articles for article (PubMed ID: 29195618)
1. Metabolic Tumor Volume Metrics in Lymphoma.
Kostakoglu L; Chauvie S
Semin Nucl Med; 2018 Jan; 48(1):50-66. PubMed ID: 29195618
[TBL] [Abstract][Full Text] [Related]
2. PET-Derived Quantitative Metrics for Response and Prognosis in Lymphoma.
Kostakoglu L; Chauvie S
PET Clin; 2019 Jul; 14(3):317-329. PubMed ID: 31084772
[TBL] [Abstract][Full Text] [Related]
3. The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma).
Chauvie S; Bergesio F; Fioroni F; Brambilla M; Biggi A; Versari A; Guerra L; Storto G; Musto P; Luminari S; Cabras MG; Balzarotti M; Rigacci L; Martelli M; Vitolo U; Federico M; Gallamini A
Phys Med; 2016 May; 32(5):651-6. PubMed ID: 27133138
[TBL] [Abstract][Full Text] [Related]
4. Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma.
Daisaki H; Tateishi U; Terauchi T; Tatsumi M; Suzuki K; Shimada N; Nishida H; Numata A; Kato K; Akashi K; Harada M
Ann Nucl Med; 2013 Apr; 27(3):225-32. PubMed ID: 23264065
[TBL] [Abstract][Full Text] [Related]
5. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
6. FDG PET/CT imaging as a biomarker in lymphoma.
Meignan M; Itti E; Gallamini A; Younes A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):623-33. PubMed ID: 25573631
[TBL] [Abstract][Full Text] [Related]
7. Quantitative PET/CT scanner performance characterization based upon the society of nuclear medicine and molecular imaging clinical trials network oncology clinical simulator phantom.
Sunderland JJ; Christian PE
J Nucl Med; 2015 Jan; 56(1):145-52. PubMed ID: 25525180
[TBL] [Abstract][Full Text] [Related]
8. Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation.
Sharma P; Gupta A; Patel C; Bakhshi S; Malhotra A; Kumar R
Ann Nucl Med; 2012 Jan; 26(1):58-66. PubMed ID: 22033780
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.
Povoski SP; Hall NC; Murrey DA; Wright CL; Martin EW
BMC Cancer; 2015 May; 15():378. PubMed ID: 25953144
[TBL] [Abstract][Full Text] [Related]
10. False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.
Ulaner GA; Lilienstein J; Gönen M; Maragulia J; Moskowitz CH; Zelenetz AD
J Clin Oncol; 2014 Jan; 32(1):51-6. PubMed ID: 24248697
[TBL] [Abstract][Full Text] [Related]
11. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
12. Variability and uncertainty of 18F-FDG PET imaging protocols for assessing inflammation in atherosclerosis: suggestions for improvement.
Huet P; Burg S; Le Guludec D; Hyafil F; Buvat I
J Nucl Med; 2015 Apr; 56(4):552-9. PubMed ID: 25722452
[TBL] [Abstract][Full Text] [Related]
13. Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.
de Jong EEC; van Elmpt W; Hoekstra OS; Groen HJM; Smit EF; Boellaard R; Lambin P; Dingemans AC
Acta Oncol; 2017 Nov; 56(11):1459-1464. PubMed ID: 28830270
[TBL] [Abstract][Full Text] [Related]
14. Does enhanced CT influence the biological GTV measurement on FDG-PET images?
Vera P; Modzelewski R; Hapdey S; Gouel P; Tilly H; Jardin F; Ruan S; Gardin I
Radiother Oncol; 2013 Jul; 108(1):86-90. PubMed ID: 23618503
[TBL] [Abstract][Full Text] [Related]
15. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
16. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
18. Radiological interpretation 2020: toward quantitative image assessment.
Boone JM
Med Phys; 2007 Nov; 34(11):4173-9. PubMed ID: 18072481
[TBL] [Abstract][Full Text] [Related]
19. Technical Note: Rod phantom analysis for comparison of PET detector sampling and reconstruction methods.
Wollenweber SD; Kemp BJ
Med Phys; 2016 Nov; 43(11):6175. PubMed ID: 27806605
[TBL] [Abstract][Full Text] [Related]
20. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
